MiR-148a inhibits angiogenesis by targeting ERBB3
MicroRNAs （miRNAs） play an important role in carcinogenesis in various solid cancers including breast can-cer. Down-regulation of microRNA-148a （miR-148a） has been reported in certain cancer types. However, the biological role of miR-148a and its related targets in breast cancer are unknown yet. In...
Saved in:
| Published in | Journal of biomedical research Vol. 25; no. 3; pp. 170 - 177 |
|---|---|
| Main Authors | , , , , |
| Format | Journal Article |
| Language | English |
| Published |
China
Elsevier B.V
01.05.2011
Editorial Department of Journal of Biomedical Research |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | MicroRNAs （miRNAs） play an important role in carcinogenesis in various solid cancers including breast can-cer. Down-regulation of microRNA-148a （miR-148a） has been reported in certain cancer types. However, the biological role of miR-148a and its related targets in breast cancer are unknown yet. In this study, we showed that the level of miR-148a was lower in MCF7 cells than that in MCF10A cells. V-erb-b2 erythroblastic leukemia viral oncogene homolog 3 （ERBB3） is a direct target of miR-148a in human breast cancer cells through direct binding of miR-148a to ERBB3 3’-UTR region. Overexpression of miR-148a in MCF7 cells inhibited ERBB3 expression, blocked the downstream pathway activation including activation of AKT, ERK1/2, and p70S6K1, and decreased HIF-1α expression. Furthermore, forced expression of miR-148a attenuated tumor angiogenesis in vivo. Our re-sults identify ERBB3 as a direct target of miR-148a, and provide direct evidence that miR-148a inhibits tumor an-giogenesis through ERBB3 and its downstream signaling molecules. This information would be helpful for target-ing the miR-148a/ERBB3 pathway for breast cancer prevention and treatment in the future. |
|---|---|
| AbstractList | MicroRNAs (miRNAs) play an important role in carcinogenesis in various solid cancers including breast cancer. Down-regulation of
microRNA
-
148a
(
miR
-
148a
) has been reported in certain cancer types. However, the biological role of
miR
-
148a
and its related targets in breast cancer are unknown yet. In this study, we showed that the level of
miR
-
148a
was lower in MCF7 cells than that in MCF10A cells. V-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (
ERBB3
) is a direct target of
miR
-
148a
in human breast cancer cells through direct binding of
miR
-
148a
to
ERBB3
3′-UTR region. Overexpression of
miR
-
148a
in MCF7 cells inhibited
ERBB3
expression, blocked the downstream pathway activation including activation of AKT, ERK1/2, and p70S6K1, and decreased HIF-1α expression. Furthermore, forced expression of
miR
-
148a
attenuated tumor angiogenesis
in vivo
. Our results identify
ERBB3
as a direct target of
miR
-
148a
, and provide direct evidence that
miR
-
148a
inhibits tumor angiogenesis through
ERBB3
and its downstream signaling molecules. This information would be helpful for targeting the
miR
-
148a
/
ERBB3
pathway for breast cancer prevention and treatment in the future. MicroRNAs (miRNAs) play an important role in carcinogenesis in various solid cancers including breast cancer. Down-regulation of microRNA-148a (miR-148a) has been reported in certain cancer types. However, the biological role of miR-148a and its related targets in breast cancer are unknown yet. In this study, we showed that the level of miR-148a was lower in MCF7 cells than that in MCF10A cells. V-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (ERBB3) is a direct target of miR-148a in human breast cancer cells through direct binding of miR-148a to ERBB3 3'-UTR region. Overexpression of miR-148a in MCF7 cells inhibited ERBB3 expression, blocked the downstream pathway activation including activation of AKT, ERK1/2, and p70S6K1, and decreased HIF-1α expression. Furthermore, forced expression of miR-148a attenuated tumor angiogenesis in vivo. Our results identify ERBB3 as a direct target of miR-148a, and provide direct evidence that miR-148a inhibits tumor angiogenesis through ERBB3 and its downstream signaling molecules. This information would be helpful for targeting the miR-148a/ERBB3 pathway for breast cancer prevention and treatment in the future. MicroRNAs (miRNAs) play an important role in carcinogenesis in various solid cancers including breast cancer. Down-regulation of microRNA-148a (miR-148a) has been reported in certain cancer types. However, the biological role of miR-148a and its related targets in breast cancer are unknown yet. In this study, we showed that the level of miR-148a was lower in MCF7 cells than that in MCF10A cells. V-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (ERBB3) is a direct target of miR-148a in human breast cancer cells through direct binding of miR-148a to ERBB3 3'-UTR region. Overexpression of miR-148a in MCF7 cells inhibited ERBB3 expression, blocked the downstream pathway activation including activation of AKT, ERK1/2, and p70S6K1, and decreased HIF-1α expression. Furthermore, forced expression of miR-148a attenuated tumor angiogenesis in vivo. Our results identify ERBB3 as a direct target of miR-148a, and provide direct evidence that miR-148a inhibits tumor angiogenesis through ERBB3 and its downstream signaling molecules. This information would be helpful for targeting the miR-148a/ERBB3 pathway for breast cancer prevention and treatment in the future.MicroRNAs (miRNAs) play an important role in carcinogenesis in various solid cancers including breast cancer. Down-regulation of microRNA-148a (miR-148a) has been reported in certain cancer types. However, the biological role of miR-148a and its related targets in breast cancer are unknown yet. In this study, we showed that the level of miR-148a was lower in MCF7 cells than that in MCF10A cells. V-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (ERBB3) is a direct target of miR-148a in human breast cancer cells through direct binding of miR-148a to ERBB3 3'-UTR region. Overexpression of miR-148a in MCF7 cells inhibited ERBB3 expression, blocked the downstream pathway activation including activation of AKT, ERK1/2, and p70S6K1, and decreased HIF-1α expression. Furthermore, forced expression of miR-148a attenuated tumor angiogenesis in vivo. Our results identify ERBB3 as a direct target of miR-148a, and provide direct evidence that miR-148a inhibits tumor angiogenesis through ERBB3 and its downstream signaling molecules. This information would be helpful for targeting the miR-148a/ERBB3 pathway for breast cancer prevention and treatment in the future. MicroRNAs （miRNAs） play an important role in carcinogenesis in various solid cancers including breast can-cer. Down-regulation of microRNA-148a （miR-148a） has been reported in certain cancer types. However, the biological role of miR-148a and its related targets in breast cancer are unknown yet. In this study, we showed that the level of miR-148a was lower in MCF7 cells than that in MCF10A cells. V-erb-b2 erythroblastic leukemia viral oncogene homolog 3 （ERBB3） is a direct target of miR-148a in human breast cancer cells through direct binding of miR-148a to ERBB3 3’-UTR region. Overexpression of miR-148a in MCF7 cells inhibited ERBB3 expression, blocked the downstream pathway activation including activation of AKT, ERK1/2, and p70S6K1, and decreased HIF-1α expression. Furthermore, forced expression of miR-148a attenuated tumor angiogenesis in vivo. Our re-sults identify ERBB3 as a direct target of miR-148a, and provide direct evidence that miR-148a inhibits tumor an-giogenesis through ERBB3 and its downstream signaling molecules. This information would be helpful for target-ing the miR-148a/ERBB3 pathway for breast cancer prevention and treatment in the future. MicroRNAs (miRNAs) play an important role in carcinogenesis in various solid cancers including breast cancer. Down-regulation of microRNA-148a ( miR-148a) has been reported in certain cancer types. However, the biological role of miR-148a and its related targets in breast cancer are unknown yet. In this study, we showed that the level of miR-148a was lower in MCF7 cells than that in MCF10A cells. V-erb-b2 erythroblastic leukemia viral oncogene homolog 3 ( ERBB3) is a direct target of miR-148a in human breast cancer cells through direct binding of miR-148a to ERBB3 3′-UTR region. Overexpression of miR-148a in MCF7 cells inhibited ERBB3 expression, blocked the downstream pathway activation including activation of AKT, ERK1/2, and p70S6K1, and decreased HIF-1α expression. Furthermore, forced expression of miR-148a attenuated tumor angiogenesis in vivo. Our results identify ERBB3 as a direct target of miR-148a, and provide direct evidence that miR-148a inhibits tumor angiogenesis through ERBB3 and its downstream signaling molecules. This information would be helpful for targeting the miR-148a/ERBB3 pathway for breast cancer prevention and treatment in the future. |
| Author | Jing Yu Qi Li Qing Xu Lingzhi Liu Binghua Jiang |
| AuthorAffiliation | Lab of Reproductive Medicine, Department of Pathology, Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Cancer Center, Nanjing Medical University, Nanjing ,Jiangsu 210029, China Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson University, Philadelphia, PA, USA. |
| AuthorAffiliation_xml | – name: b Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson University, Philadelphia, PA, USA – name: a Lab of Reproductive Medicine, Department of Pathology, Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Cancer Center, Nanjing Medical University, Nanjing, Jiangsu 210029, China |
| Author_xml | – sequence: 1 givenname: Jing surname: Yu fullname: Yu, Jing organization: Lab of Reproductive Medicine, Department of Pathology, Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Cancer Center, Nanjing Medical University, Nanjing, Jiangsu 210029, China – sequence: 2 givenname: Qi surname: Li fullname: Li, Qi organization: Lab of Reproductive Medicine, Department of Pathology, Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Cancer Center, Nanjing Medical University, Nanjing, Jiangsu 210029, China – sequence: 3 givenname: Qing surname: Xu fullname: Xu, Qing organization: Lab of Reproductive Medicine, Department of Pathology, Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Cancer Center, Nanjing Medical University, Nanjing, Jiangsu 210029, China – sequence: 4 givenname: Lingzhi surname: Liu fullname: Liu, Lingzhi organization: Lab of Reproductive Medicine, Department of Pathology, Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Cancer Center, Nanjing Medical University, Nanjing, Jiangsu 210029, China – sequence: 5 givenname: Binghua surname: Jiang fullname: Jiang, Binghua email: bing-hjiang@yahoo.com organization: Lab of Reproductive Medicine, Department of Pathology, Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Cancer Center, Nanjing Medical University, Nanjing, Jiangsu 210029, China |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/23554686$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFUU1vFCEY5lBja-1P0Iy3ehjlHWBgYqKxTW1NakyqngnDvMxiZqEFtkn_vTPuulEv5UICz1ee5xk5CDEgIS-AvgEK7dsMreS1YhROAV63lDZNLQ7I0f75kJzk_JPOh3Vtw9VTctgwIXir2iMCX_xNDVyZyoeV733JlQmjjyMGzD5X_UNVTBqx-DBWFzdnZ-w5eeLMlPFkdx-TH58uvp9f1ddfLz-ff7yurRBdqYUU0siWOddL04mho2YwYnBucGCh77u-Ac7snM81TimDUgxMSobGcWnBsGPyfqt7u-nXOFgMJZlJ3ya_NulBR-P1vz_Br_QY7zUTnaQtzAKnO4EU7zaYi177bHGaTMC4yRpYw5lSc9AZ-vJvr73Jn55mgNgCbIo5J3R7CFC9zKC_LX3rpW8NoH_PoBfhd__xrC-m-LhE9tOj7A9bNs4933tMOluPweLgE9qih-gfVXi181_FMN7NI-6DM8W45IqxX2o0rVM |
| CitedBy_id | crossref_primary_10_3389_fimmu_2023_1125257 crossref_primary_10_3389_fonc_2023_1258365 crossref_primary_10_1080_21645515_2015_1102809 crossref_primary_10_1007_s13277_015_4688_0 crossref_primary_10_1016_j_biopha_2019_109058 crossref_primary_10_1038_s41598_018_35947_7 crossref_primary_10_1371_journal_pone_0101950 crossref_primary_10_1038_jhg_2016_89 crossref_primary_10_1039_C8RA10224D crossref_primary_10_1186_s13046_018_0748_9 crossref_primary_10_3390_ijms23095107 crossref_primary_10_1038_s41419_020_03304_0 crossref_primary_10_1007_s11033_020_05250_8 crossref_primary_10_1002_jcp_28232 crossref_primary_10_1186_s12885_017_3751_1 crossref_primary_10_18632_oncotarget_7953 crossref_primary_10_1021_acs_jafc_2c00631 crossref_primary_10_1038_onc_2013_369 crossref_primary_10_1186_s12885_017_3298_1 crossref_primary_10_1016_j_abb_2015_07_022 crossref_primary_10_1038_onc_2015_475 crossref_primary_10_1093_carcin_bgz130 crossref_primary_10_1002_eji_201747132 crossref_primary_10_1016_j_bbrc_2017_01_012 crossref_primary_10_1159_000438826 crossref_primary_10_3390_ijms21041386 crossref_primary_10_1002_mc_22333 crossref_primary_10_3892_ol_2019_10581 crossref_primary_10_3390_cancers13194894 crossref_primary_10_1016_j_jare_2021_06_019 crossref_primary_10_1038_s41416_021_01677_3 crossref_primary_10_1038_s41388_019_0922_3 crossref_primary_10_3892_etm_2017_4255 crossref_primary_10_1097_MOP_0000000000000268 crossref_primary_10_1186_s12935_017_0449_z crossref_primary_10_1186_s12885_017_3575_z crossref_primary_10_1016_j_lfs_2024_123087 crossref_primary_10_1002_mnfr_201700009 crossref_primary_10_1016_j_fob_2015_05_009 crossref_primary_10_1016_j_gene_2014_08_041 crossref_primary_10_3390_ijms21197327 crossref_primary_10_1016_j_heliyon_2024_e24803 crossref_primary_10_1016_j_semcancer_2020_12_025 crossref_primary_10_1016_j_bbrc_2014_07_073 crossref_primary_10_3892_or_2015_4502 crossref_primary_10_3390_ijms221910890 crossref_primary_10_1111_jcmm_14257 crossref_primary_10_1161_CIRCULATIONAHA_114_012975 crossref_primary_10_3892_etm_2018_6845 crossref_primary_10_1080_19420862_2017_1319023 crossref_primary_10_1016_j_yexcr_2021_112518 crossref_primary_10_1016_j_bbrep_2021_101060 crossref_primary_10_1186_s12943_018_0862_5 crossref_primary_10_1186_s40104_016_0068_x crossref_primary_10_1016_j_mgene_2014_01_002 crossref_primary_10_3390_biomedicines3010032 |
| Cites_doi | 10.1073/pnas.040560897 10.1038/nature03702 10.1016/j.ccr.2008.10.005 10.1002/path.2759 10.1158/0008-5472.CAN-10-2412 10.1038/ng1855 10.1182/blood-2009-06-229211 10.1074/jbc.M709382200 10.1093/nar/gni178 10.1245/s10434-010-1213-y 10.1038/nrc1187 10.1038/onc.2010.180 10.1007/s11605-010-1202-2 10.1016/S0092-8674(01)00616-X 10.1038/cr.2009.18 10.1074/jbc.M109.079525 10.1002/hep.23381 10.1056/NEJM199512283332608 10.1038/nrc2867 10.1261/rna.1460509 10.1038/nm0810-853 10.1093/emboj/19.13.3159 10.1182/blood-2010-06-290536 10.1261/rna.972008 10.1158/0008-5472.CAN-09-3321 10.1038/pcan.2010.32 10.1038/339058a0 10.1038/ng865 10.1210/en.2002-220620 10.2325/jbcs.977 10.1073/pnas.0803055105 10.1073/pnas.0706901104 10.1038/sj.onc.1203931 10.1074/jbc.M609383200 10.1038/bjc.1992.420 |
| ContentType | Journal Article |
| Copyright | 2011 The Editorial Board of Journal of Biomedical Research 2011 by the Journal of Biomedical Research. All rights reserved. 2011 |
| Copyright_xml | – notice: 2011 The Editorial Board of Journal of Biomedical Research – notice: 2011 by the Journal of Biomedical Research. All rights reserved. 2011 |
| DBID | 2RA 92L CQIGP W91 ~WA AAYXX CITATION NPM 7X8 5PM |
| DOI | 10.1016/s1674-8301(11)60022-5 |
| DatabaseName | 维普期刊资源整合服务平台 中文科技期刊数据库-CALIS站点 中文科技期刊数据库-7.0平台 中文科技期刊数据库-医药卫生 中文科技期刊数据库- 镜像站点 CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | PubMed MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| DocumentTitleAlternate | MiR-148a inhibits angiogenesis by targeting ERBB3 |
| EndPage | 177 |
| ExternalDocumentID | PMC3597061 23554686 10_1016_S1674_8301_11_60022_5 S1674830111600225 38347483 |
| Genre | Journal Article |
| GrantInformation_xml | – fundername: the National Natural Science Foundation of China grantid: (No. 30871296 and No. 81071642) |
| GroupedDBID | --- --K .~1 0R~ 1B1 1~. 1~5 2B. 2C~ 2RA 4.4 457 4G. 5VR 5VS 7-5 71M 92F 92I 92L 93N 93R AAEDT AALRI AAQFI AAXUO ABBQC ABDBF ABYKQ ADRAZ AEGXH AEKER AFUIB AGYEJ AITUG AJBFU AJRQY ALMA_UNASSIGNED_HOLDINGS AMFUW CCEZO CHBEP CIEJG CQIGP CW9 DIK EBD EBS EJD EOJEC FA0 FDB FEDTE FNPLU GBLVA GX1 HVGLF HYE HZ~ J1W KQ8 M41 M48 MO0 N9A O-L O9- OBODZ OK1 OZT P-8 P-9 P6G PC. Q38 RIG RNS ROL RPM SDF SES TCJ TGQ TUS W91 WFFXF ~WA -SE -S~ AAYXX ACUHS AIGII CAJEE CITATION Q-- U1G U5O NPM 7X8 5PM |
| ID | FETCH-LOGICAL-c559t-5757a763ffb7a95d90ada5dffdf1c1bb9b2143c301f2f88ae75d3773eaf47c1a3 |
| IEDL.DBID | M48 |
| ISSN | 1674-8301 |
| IngestDate | Thu Aug 21 18:30:46 EDT 2025 Fri Jul 11 09:52:21 EDT 2025 Mon Jul 21 06:05:27 EDT 2025 Thu Apr 24 23:08:25 EDT 2025 Tue Aug 05 12:07:14 EDT 2025 Fri Feb 23 02:25:48 EST 2024 Wed Feb 14 09:54:20 EST 2024 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Keywords | breast cancer microRNA-148a ERBB3 angiogenesis |
| Language | English |
| License | https://www.elsevier.com/tdm/userlicense/1.0 This work is licensed under a Creative Commons Attribution 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by/3.0 |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c559t-5757a763ffb7a95d90ada5dffdf1c1bb9b2143c301f2f88ae75d3773eaf47c1a3 |
| Notes | MicroRNAs （miRNAs） play an important role in carcinogenesis in various solid cancers including breast can-cer. Down-regulation of microRNA-148a （miR-148a） has been reported in certain cancer types. However, the biological role of miR-148a and its related targets in breast cancer are unknown yet. In this study, we showed that the level of miR-148a was lower in MCF7 cells than that in MCF10A cells. V-erb-b2 erythroblastic leukemia viral oncogene homolog 3 （ERBB3） is a direct target of miR-148a in human breast cancer cells through direct binding of miR-148a to ERBB3 3’-UTR region. Overexpression of miR-148a in MCF7 cells inhibited ERBB3 expression, blocked the downstream pathway activation including activation of AKT, ERK1/2, and p70S6K1, and decreased HIF-1α expression. Furthermore, forced expression of miR-148a attenuated tumor angiogenesis in vivo. Our re-sults identify ERBB3 as a direct target of miR-148a, and provide direct evidence that miR-148a inhibits tumor an-giogenesis through ERBB3 and its downstream signaling molecules. This information would be helpful for target-ing the miR-148a/ERBB3 pathway for breast cancer prevention and treatment in the future. breast cancer; microRNA-148a; angiogenesis; ERBB3 32-1810/R ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 These authors reported no conflict of interests. |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1016/S1674-8301(11)60022-5 |
| PMID | 23554686 |
| PQID | 1324388575 |
| PQPubID | 23479 |
| PageCount | 8 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_3597061 proquest_miscellaneous_1324388575 pubmed_primary_23554686 crossref_primary_10_1016_S1674_8301_11_60022_5 crossref_citationtrail_10_1016_S1674_8301_11_60022_5 elsevier_sciencedirect_doi_10_1016_S1674_8301_11_60022_5 chongqing_primary_38347483 |
| PublicationCentury | 2000 |
| PublicationDate | 2011-05-00 |
| PublicationDateYYYYMMDD | 2011-05-01 |
| PublicationDate_xml | – month: 05 year: 2011 text: 2011-05-00 |
| PublicationDecade | 2010 |
| PublicationPlace | China |
| PublicationPlace_xml | – name: China |
| PublicationTitle | Journal of biomedical research |
| PublicationTitleAlternate | Journal of Biomedical Research |
| PublicationYear | 2011 |
| Publisher | Elsevier B.V Editorial Department of Journal of Biomedical Research |
| Publisher_xml | – name: Elsevier B.V – name: Editorial Department of Journal of Biomedical Research |
| References | Chen, Ridzon, Broomer, Zhou, Lee, Nguyen (bib36) 2005; 33 Kamalati, Jolin, Fry, Crompton (bib24) 2000; 19 Chen, Song, Wang, Yue, Xu, Xing (bib7) 2010; 14 Lujambio, Calin, Villanueva, Ropero, Sanchez-Cespedes, Blanco (bib10) 2008; 105 Tchernitsa, Kasajima, Schafer, Kuban, Ungethum, Gyorffy (bib5) 2010; 222 Wurdinger, Tannous, Saydam, Skog, Grau, Soutschek (bib28) 2008; 14 Hatake, Tokudome, Ito (bib30) 2007; 14 Visone, Rassenti, Veronese, Taccioli, Costinean, Aguda (bib6) 2009; 114 Huang, Gao, Wang, McManaman, Thor, Yang (bib19) 2010; 70 Takagi, Nakajima, Mohri, Yokoi (bib14) 2008; 283 Duursma, Kedde, Schrier, le Sage, Agami (bib13) 2008; 14 Scott, Goga, Bhaumik, Berger, Sullivan, Benz (bib21) 2007; 282 Knowlden, Hutcheson, Jones, Madden, Gee, Harper (bib25) 2003; 144 Ryan, Robles, Harris (bib3) 2010; 10 Wu, Zhu, Mo (bib20) 2009; 19 Folkman, Watson, Ingber, Hanahan (bib22) 1989; 339 Lee, Deng, Wang, Yang (bib27) 2007; 104 Ambros (bib2) 2001; 107 Lu, Getz, Miska, Alvarez-Saavedra, Lamb, Peck (bib4) 2005; 435 Braconi, Huang, Patel (bib15) 2010; 51 Eilken, Adams (bib23) 2010; 16 Schwind, Marcucci, Maharry, Radmacher, Mrozek, Holland (bib9) 2010; 116 Navolanic, Steelman, McCubrey (bib31) 2003; 22 Dews, Fox, Hultine, Sundaram, Wang, Liu (bib29) 2010; 70 Yarden, Sliwkowski (bib17) 2001; 2 Dews, Homayouni, Yu, Murphy, Sevignani, Wentzel (bib32) 2006; 38 Semenza (bib34) 2003; 3 Fujita, Kojima, Ohhashi, Hamada, Nozawa, Kitamoto (bib11) 2010; 285 Wang (bib35) 2009; 15 Folkman (bib26) 1995; 333 Olayioye, Neve, Lane, Hynes (bib16) 2000; 19 Hummel, Hussey, Michael, Haier, Bruewer, Senninger (bib8) 2011; 18 Jiang, Zheng, Aoki, Vogt (bib37) 2000; 97 Lai (bib1) 2002; 30 Wang, Huang, Lee, Liu (bib33) 2010; 29 Murata, Takayama, Katayama, Urano, Ho-rie-Inoue, Ikeda (bib12) 2010; 13 Lemoine, Barnes, Hollywood, Hughes, Smith, Dublin (bib18) 1992; 66 Yarden (10.1016/S1674-8301(11)60022-5_bib17) 2001; 2 Dews (10.1016/S1674-8301(11)60022-5_bib32) 2006; 38 Chen (10.1016/S1674-8301(11)60022-5_bib7) 2010; 14 Folkman (10.1016/S1674-8301(11)60022-5_bib26) 1995; 333 Dews (10.1016/S1674-8301(11)60022-5_bib29) 2010; 70 Jiang (10.1016/S1674-8301(11)60022-5_bib37) 2000; 97 Ryan (10.1016/S1674-8301(11)60022-5_bib3) 2010; 10 Visone (10.1016/S1674-8301(11)60022-5_bib6) 2009; 114 Hummel (10.1016/S1674-8301(11)60022-5_bib8) 2011; 18 Scott (10.1016/S1674-8301(11)60022-5_bib21) 2007; 282 Hatake (10.1016/S1674-8301(11)60022-5_bib30) 2007; 14 Wurdinger (10.1016/S1674-8301(11)60022-5_bib28) 2008; 14 Lai (10.1016/S1674-8301(11)60022-5_bib1) 2002; 30 Huang (10.1016/S1674-8301(11)60022-5_bib19) 2010; 70 Lu (10.1016/S1674-8301(11)60022-5_bib4) 2005; 435 Kamalati (10.1016/S1674-8301(11)60022-5_bib24) 2000; 19 Braconi (10.1016/S1674-8301(11)60022-5_bib15) 2010; 51 Knowlden (10.1016/S1674-8301(11)60022-5_bib25) 2003; 144 Semenza (10.1016/S1674-8301(11)60022-5_bib34) 2003; 3 Lujambio (10.1016/S1674-8301(11)60022-5_bib10) 2008; 105 Wang (10.1016/S1674-8301(11)60022-5_bib35) 2009; 15 Schwind (10.1016/S1674-8301(11)60022-5_bib9) 2010; 116 Lemoine (10.1016/S1674-8301(11)60022-5_bib18) 1992; 66 Duursma (10.1016/S1674-8301(11)60022-5_bib13) 2008; 14 Tchernitsa (10.1016/S1674-8301(11)60022-5_bib5) 2010; 222 Lee (10.1016/S1674-8301(11)60022-5_bib27) 2007; 104 Fujita (10.1016/S1674-8301(11)60022-5_bib11) 2010; 285 Chen (10.1016/S1674-8301(11)60022-5_bib36) 2005; 33 Takagi (10.1016/S1674-8301(11)60022-5_bib14) 2008; 283 Folkman (10.1016/S1674-8301(11)60022-5_bib22) 1989; 339 Eilken (10.1016/S1674-8301(11)60022-5_bib23) 2010; 16 Navolanic (10.1016/S1674-8301(11)60022-5_bib31) 2003; 22 Murata (10.1016/S1674-8301(11)60022-5_bib12) 2010; 13 Wu (10.1016/S1674-8301(11)60022-5_bib20) 2009; 19 Ambros (10.1016/S1674-8301(11)60022-5_bib2) 2001; 107 Wang (10.1016/S1674-8301(11)60022-5_bib33) 2010; 29 Olayioye (10.1016/S1674-8301(11)60022-5_bib16) 2000; 19 20628822 - Ann Surg Oncol. 2011 Jan;18(1):253-60 18367714 - RNA. 2008 May;14(5):872-7 2469964 - Nature. 1989 May 4;339(6219):58-61 12586780 - Endocrinology. 2003 Mar;144(3):1032-44 18077375 - Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20350-5 18768788 - Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13556-61 16314309 - Nucleic Acids Res. 2005 Nov 27;33(20):e179 17485898 - Breast Cancer. 2007;14(2):132-49 19218553 - RNA. 2009 Apr;15(4):716-23 11252954 - Nat Rev Mol Cell Biol. 2001 Feb;2(2):127-37 20103628 - Cancer Res. 2010 Feb 1;70(3):1204-14 10880430 - EMBO J. 2000 Jul 3;19(13):3159-67 20820187 - Prostate Cancer Prostatic Dis. 2010 Dec;13(4):356-61 11896390 - Nat Genet. 2002 Apr;30(4):363-4 19717645 - Blood. 2009 Oct 29;114(18):3872-9 20726036 - J Pathol. 2010 Nov;222(3):310-9 18268015 - J Biol Chem. 2008 Apr 11;283(15):9674-80 20495573 - Nat Rev Cancer. 2010 Jun;10(6):389-402 12527919 - Int J Oncol. 2003 Feb;22(2):237-52 15944708 - Nature. 2005 Jun 9;435(7043):834-8 20841507 - Blood. 2010 Dec 16;116(25):5660-9 10677529 - Proc Natl Acad Sci U S A. 2000 Feb 15;97(4):1749-53 7491141 - N Engl J Med. 1995 Dec 28;333(26):1757-63 18977327 - Cancer Cell. 2008 Nov 4;14(5):382-93 20146264 - Hepatology. 2010 Mar;51(3):881-90 20422307 - J Gastrointest Surg. 2010 Jul;14(7):1170-9 20940405 - Cancer Res. 2010 Oct 15;70(20):8233-46 11779458 - Cell. 2001 Dec 28;107(7):823-6 20498641 - Oncogene. 2010 Jul 22;29(29):4225-36 1333787 - Br J Cancer. 1992 Dec;66(6):1116-21 17110380 - J Biol Chem. 2007 Jan 12;282(2):1479-86 20406806 - J Biol Chem. 2010 Jun 18;285(25):19076-84 16878133 - Nat Genet. 2006 Sep;38(9):1060-5 20689545 - Nat Med. 2010 Aug;16(8):853-4 19238171 - Cell Res. 2009 Apr;19(4):439-48 11114724 - Oncogene. 2000 Nov 16;19(48):5471-6 13130303 - Nat Rev Cancer. 2003 Oct;3(10):721-32 |
| References_xml | – volume: 10 start-page: 389 year: 2010 end-page: 402 ident: bib3 article-title: Harris. Genetic variation in microRNA networks: the implications for cancer research publication-title: Nat Rev Cancer – volume: 105 start-page: 13556 year: 2008 end-page: 13561 ident: bib10 article-title: A microR-NA DNA methylation signature for human cancer metastasis publication-title: Proc Natl Acad Sci U S A – volume: 282 start-page: 1479 year: 2007 end-page: 1486 ident: bib21 article-title: Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b publication-title: J Biol Chem – volume: 13 start-page: 356 year: 2010 end-page: 361 ident: bib12 article-title: miR-148a is an andro-gen-responsive microRNA that promotes LNCaP prostate cell growth by repressing its target CAND1 expression publication-title: Prostate Cancer Prostatic Dis – volume: 435 start-page: 834 year: 2005 end-page: 838 ident: bib4 article-title: MicroRNA expression profiles classify human cancers publication-title: Nature – volume: 15 start-page: 716 year: 2009 end-page: 723 ident: bib35 article-title: A PCR-based platform for microRNA expression profiling studies publication-title: RNA – volume: 285 start-page: 19076 year: 2010 end-page: 19084 ident: bib11 article-title: MiR-148a attenuates paclitaxel resistance of hormone-refractory, drug-resistant prostate cancer PC3 cells by regulating MSK1 expression publication-title: J Biol Chem – volume: 51 start-page: 881 year: 2010 end-page: 890 ident: bib15 article-title: MicroRNA-dependent regulation of DNA methyltransferase-1 and tumor suppressor gene expression by interleukin-6 in human malignant cholangiocytes publication-title: Hepatology – volume: 18 start-page: 253 year: 2011 end-page: 260 ident: bib8 article-title: MiRNAs and Their Association with Locoregional Staging and Survival Following Surgery for Esophageal Carcinoma publication-title: Ann Surg Oncol – volume: 14 start-page: 382 year: 2008 end-page: 393 ident: bib28 article-title: miR-296 regulates growth factor receptor overexpression in angiogenic endothelial cells publication-title: Cancer Cell – volume: 97 start-page: 1749 year: 2000 end-page: 1753 ident: bib37 article-title: Phosphatidylinositol 3-kinase signaling mediates angiogenesis and expression of vascular endothelial growth factor in endothelial cells publication-title: Proc Natl Acad Sci U S A – volume: 19 start-page: 439 year: 2009 end-page: 448 ident: bib20 article-title: Suppression of cell growth and invasion by miR-205 in breast cancer publication-title: Cell Res – volume: 339 start-page: 58 year: 1989 end-page: 61 ident: bib22 article-title: Induction of angiogenesis during the transition from hyperplasia to neoplasia publication-title: Nature – volume: 144 start-page: 1032 year: 2003 end-page: 1044 ident: bib25 article-title: Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells publication-title: Endocrinology – volume: 30 start-page: 363 year: 2002 end-page: 364 ident: bib1 article-title: Micro RNAs are complementary to 3′ UTR sequence motifs that mediate negative post-transcriptional regulation publication-title: Nat Genet – volume: 283 start-page: 9674 year: 2008 end-page: 9680 ident: bib14 article-title: Post-transcriptional regulation of human pregnane X receptor by micro-RNA affects the expression of cytochrome P450 3A4 publication-title: J Biol Chem – volume: 22 start-page: 237 year: 2003 end-page: 252 ident: bib31 article-title: EGFR family signaling and its association with breast cancer development and resistance to chemotherapy (Review). Int publication-title: Oncol – volume: 107 start-page: 823 year: 2001 end-page: 826 ident: bib2 article-title: microRNAs: tiny regulators with great potential publication-title: Cell – volume: 222 start-page: 310 year: 2010 end-page: 319 ident: bib5 article-title: Systematic evaluation of the miRNA-ome and its downstream effects on mRNA expression identifies gastric cancer progression publication-title: J Pathol – volume: 38 start-page: 1060 year: 2006 end-page: 1065 ident: bib32 article-title: Augmentation of tumor angiogenesis by a Mycactivated microRNA cluster publication-title: Nat Genet – volume: 14 start-page: 1170 year: 2010 end-page: 1179 ident: bib7 article-title: Altered expression of MiR-148a and MiR-152 in gastrointestinal cancers and its clinical significance publication-title: J Gastrointest Surg – volume: 114 start-page: 3872 year: 2009 end-page: 3879 ident: bib6 article-title: Karyotype-specific microRNA signature in chronic lymphocytic leukemia publication-title: Blood – volume: 66 start-page: 1116 year: 1992 end-page: 1121 ident: bib18 article-title: Expression of the ERBB3 gene product in breast cancer publication-title: Br J Cancer – volume: 19 start-page: 3159 year: 2000 end-page: 3167 ident: bib16 article-title: The ErbB signaling network: receptor heterodimerization in development and cancer publication-title: EMBO J – volume: 19 start-page: 5471 year: 2000 end-page: 5476 ident: bib24 article-title: Expression of the BRK tyrosine kinase in mammary epithelial cells enhances the coupling of EGF signalling to PI 3-kinase and Akt, via erbB3 phosphorylation publication-title: Oncogene – volume: 14 start-page: 132 year: 2007 end-page: 149 ident: bib30 article-title: Next generation molecular targeted agents for breast cancer: focus on EGFR and VEGFR pathways publication-title: Breast Cancer – volume: 33 start-page: e179 year: 2005 ident: bib36 article-title: Realtime quantification of microRNAs by stem-loop RT-PCR publication-title: Nucleic Acids Res – volume: 14 start-page: 872 year: 2008 end-page: 877 ident: bib13 article-title: miR-148 targets human DNMT3b protein coding region publication-title: RNA – volume: 70 start-page: 8233 year: 2010 end-page: 8246 ident: bib29 article-title: The myc-miR-17∼92 axis blunts TGF{beta} signaling and production of multiple TGF{beta}-dependent antiangiogenic factors publication-title: Cancer Res – volume: 70 start-page: 1204 year: 2010 end-page: 1214 ident: bib19 article-title: Heterotrimerization of the growth factor receptors erbB2, erbB3, and insulin-like growth factori receptor in breast cancer cells resistant to herceptin publication-title: Cancer Res – volume: 16 start-page: 853 year: 2010 end-page: 854 ident: bib23 article-title: Turning on the angiogenic microswitch publication-title: Nat Med – volume: 29 start-page: 4225 year: 2010 end-page: 4236 ident: bib33 article-title: Elevated expression of erbB3 confers paclitaxel resistance in erbB2-overexpressing breast cancer cells via upregulation of Survivin publication-title: Oncogene – volume: 2 start-page: 127 year: 2001 end-page: 137 ident: bib17 article-title: Untangling the ErbB signalling network. Nat. Rev publication-title: Mol Cell Biol – volume: 3 start-page: 721 year: 2003 end-page: 732 ident: bib34 article-title: Targeting HIF-1 for cancer therapy publication-title: Nat Rev Cancer – volume: 333 start-page: 1757 year: 1995 end-page: 1763 ident: bib26 article-title: Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis publication-title: N Engl J Med – volume: 116 start-page: 5660 year: 2010 end-page: 5669 ident: bib9 article-title: BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study publication-title: Blood – volume: 104 start-page: 20350 year: 2007 end-page: 20355 ident: bib27 article-title: Micro-RNA-378 promotes cell survival, tumor growth, and angiogenesis by targeting SuFu and Fus-1 expression publication-title: Proc Natl Acad Sci U S A – volume: 97 start-page: 1749 year: 2000 ident: 10.1016/S1674-8301(11)60022-5_bib37 article-title: Phosphatidylinositol 3-kinase signaling mediates angiogenesis and expression of vascular endothelial growth factor in endothelial cells publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.040560897 – volume: 435 start-page: 834 year: 2005 ident: 10.1016/S1674-8301(11)60022-5_bib4 article-title: MicroRNA expression profiles classify human cancers publication-title: Nature doi: 10.1038/nature03702 – volume: 14 start-page: 382 year: 2008 ident: 10.1016/S1674-8301(11)60022-5_bib28 article-title: miR-296 regulates growth factor receptor overexpression in angiogenic endothelial cells publication-title: Cancer Cell doi: 10.1016/j.ccr.2008.10.005 – volume: 222 start-page: 310 year: 2010 ident: 10.1016/S1674-8301(11)60022-5_bib5 article-title: Systematic evaluation of the miRNA-ome and its downstream effects on mRNA expression identifies gastric cancer progression publication-title: J Pathol doi: 10.1002/path.2759 – volume: 70 start-page: 8233 year: 2010 ident: 10.1016/S1674-8301(11)60022-5_bib29 article-title: The myc-miR-17∼92 axis blunts TGF{beta} signaling and production of multiple TGF{beta}-dependent antiangiogenic factors publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-10-2412 – volume: 38 start-page: 1060 year: 2006 ident: 10.1016/S1674-8301(11)60022-5_bib32 article-title: Augmentation of tumor angiogenesis by a Mycactivated microRNA cluster publication-title: Nat Genet doi: 10.1038/ng1855 – volume: 114 start-page: 3872 year: 2009 ident: 10.1016/S1674-8301(11)60022-5_bib6 article-title: Karyotype-specific microRNA signature in chronic lymphocytic leukemia publication-title: Blood doi: 10.1182/blood-2009-06-229211 – volume: 283 start-page: 9674 year: 2008 ident: 10.1016/S1674-8301(11)60022-5_bib14 article-title: Post-transcriptional regulation of human pregnane X receptor by micro-RNA affects the expression of cytochrome P450 3A4 publication-title: J Biol Chem doi: 10.1074/jbc.M709382200 – volume: 33 start-page: e179 year: 2005 ident: 10.1016/S1674-8301(11)60022-5_bib36 article-title: Realtime quantification of microRNAs by stem-loop RT-PCR publication-title: Nucleic Acids Res doi: 10.1093/nar/gni178 – volume: 18 start-page: 253 year: 2011 ident: 10.1016/S1674-8301(11)60022-5_bib8 article-title: MiRNAs and Their Association with Locoregional Staging and Survival Following Surgery for Esophageal Carcinoma publication-title: Ann Surg Oncol doi: 10.1245/s10434-010-1213-y – volume: 3 start-page: 721 year: 2003 ident: 10.1016/S1674-8301(11)60022-5_bib34 article-title: Targeting HIF-1 for cancer therapy publication-title: Nat Rev Cancer doi: 10.1038/nrc1187 – volume: 29 start-page: 4225 year: 2010 ident: 10.1016/S1674-8301(11)60022-5_bib33 article-title: Elevated expression of erbB3 confers paclitaxel resistance in erbB2-overexpressing breast cancer cells via upregulation of Survivin publication-title: Oncogene doi: 10.1038/onc.2010.180 – volume: 14 start-page: 1170 year: 2010 ident: 10.1016/S1674-8301(11)60022-5_bib7 article-title: Altered expression of MiR-148a and MiR-152 in gastrointestinal cancers and its clinical significance publication-title: J Gastrointest Surg doi: 10.1007/s11605-010-1202-2 – volume: 107 start-page: 823 year: 2001 ident: 10.1016/S1674-8301(11)60022-5_bib2 article-title: microRNAs: tiny regulators with great potential publication-title: Cell doi: 10.1016/S0092-8674(01)00616-X – volume: 19 start-page: 439 year: 2009 ident: 10.1016/S1674-8301(11)60022-5_bib20 article-title: Suppression of cell growth and invasion by miR-205 in breast cancer publication-title: Cell Res doi: 10.1038/cr.2009.18 – volume: 285 start-page: 19076 year: 2010 ident: 10.1016/S1674-8301(11)60022-5_bib11 article-title: MiR-148a attenuates paclitaxel resistance of hormone-refractory, drug-resistant prostate cancer PC3 cells by regulating MSK1 expression publication-title: J Biol Chem doi: 10.1074/jbc.M109.079525 – volume: 51 start-page: 881 year: 2010 ident: 10.1016/S1674-8301(11)60022-5_bib15 article-title: MicroRNA-dependent regulation of DNA methyltransferase-1 and tumor suppressor gene expression by interleukin-6 in human malignant cholangiocytes publication-title: Hepatology doi: 10.1002/hep.23381 – volume: 333 start-page: 1757 year: 1995 ident: 10.1016/S1674-8301(11)60022-5_bib26 article-title: Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis publication-title: N Engl J Med doi: 10.1056/NEJM199512283332608 – volume: 10 start-page: 389 year: 2010 ident: 10.1016/S1674-8301(11)60022-5_bib3 article-title: Harris. Genetic variation in microRNA networks: the implications for cancer research publication-title: Nat Rev Cancer doi: 10.1038/nrc2867 – volume: 15 start-page: 716 year: 2009 ident: 10.1016/S1674-8301(11)60022-5_bib35 article-title: A PCR-based platform for microRNA expression profiling studies publication-title: RNA doi: 10.1261/rna.1460509 – volume: 16 start-page: 853 year: 2010 ident: 10.1016/S1674-8301(11)60022-5_bib23 article-title: Turning on the angiogenic microswitch publication-title: Nat Med doi: 10.1038/nm0810-853 – volume: 19 start-page: 3159 year: 2000 ident: 10.1016/S1674-8301(11)60022-5_bib16 article-title: The ErbB signaling network: receptor heterodimerization in development and cancer publication-title: EMBO J doi: 10.1093/emboj/19.13.3159 – volume: 22 start-page: 237 year: 2003 ident: 10.1016/S1674-8301(11)60022-5_bib31 article-title: EGFR family signaling and its association with breast cancer development and resistance to chemotherapy (Review). Int publication-title: Oncol – volume: 116 start-page: 5660 year: 2010 ident: 10.1016/S1674-8301(11)60022-5_bib9 article-title: BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study publication-title: Blood doi: 10.1182/blood-2010-06-290536 – volume: 14 start-page: 872 year: 2008 ident: 10.1016/S1674-8301(11)60022-5_bib13 article-title: miR-148 targets human DNMT3b protein coding region publication-title: RNA doi: 10.1261/rna.972008 – volume: 70 start-page: 1204 year: 2010 ident: 10.1016/S1674-8301(11)60022-5_bib19 article-title: Heterotrimerization of the growth factor receptors erbB2, erbB3, and insulin-like growth factori receptor in breast cancer cells resistant to herceptin publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-09-3321 – volume: 13 start-page: 356 year: 2010 ident: 10.1016/S1674-8301(11)60022-5_bib12 article-title: miR-148a is an andro-gen-responsive microRNA that promotes LNCaP prostate cell growth by repressing its target CAND1 expression publication-title: Prostate Cancer Prostatic Dis doi: 10.1038/pcan.2010.32 – volume: 339 start-page: 58 year: 1989 ident: 10.1016/S1674-8301(11)60022-5_bib22 article-title: Induction of angiogenesis during the transition from hyperplasia to neoplasia publication-title: Nature doi: 10.1038/339058a0 – volume: 30 start-page: 363 year: 2002 ident: 10.1016/S1674-8301(11)60022-5_bib1 article-title: Micro RNAs are complementary to 3′ UTR sequence motifs that mediate negative post-transcriptional regulation publication-title: Nat Genet doi: 10.1038/ng865 – volume: 144 start-page: 1032 year: 2003 ident: 10.1016/S1674-8301(11)60022-5_bib25 article-title: Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells publication-title: Endocrinology doi: 10.1210/en.2002-220620 – volume: 14 start-page: 132 year: 2007 ident: 10.1016/S1674-8301(11)60022-5_bib30 article-title: Next generation molecular targeted agents for breast cancer: focus on EGFR and VEGFR pathways publication-title: Breast Cancer doi: 10.2325/jbcs.977 – volume: 105 start-page: 13556 year: 2008 ident: 10.1016/S1674-8301(11)60022-5_bib10 article-title: A microR-NA DNA methylation signature for human cancer metastasis publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.0803055105 – volume: 104 start-page: 20350 year: 2007 ident: 10.1016/S1674-8301(11)60022-5_bib27 article-title: Micro-RNA-378 promotes cell survival, tumor growth, and angiogenesis by targeting SuFu and Fus-1 expression publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.0706901104 – volume: 19 start-page: 5471 year: 2000 ident: 10.1016/S1674-8301(11)60022-5_bib24 article-title: Expression of the BRK tyrosine kinase in mammary epithelial cells enhances the coupling of EGF signalling to PI 3-kinase and Akt, via erbB3 phosphorylation publication-title: Oncogene doi: 10.1038/sj.onc.1203931 – volume: 2 start-page: 127 year: 2001 ident: 10.1016/S1674-8301(11)60022-5_bib17 article-title: Untangling the ErbB signalling network. Nat. Rev publication-title: Mol Cell Biol – volume: 282 start-page: 1479 year: 2007 ident: 10.1016/S1674-8301(11)60022-5_bib21 article-title: Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b publication-title: J Biol Chem doi: 10.1074/jbc.M609383200 – volume: 66 start-page: 1116 year: 1992 ident: 10.1016/S1674-8301(11)60022-5_bib18 article-title: Expression of the ERBB3 gene product in breast cancer publication-title: Br J Cancer doi: 10.1038/bjc.1992.420 – reference: 20146264 - Hepatology. 2010 Mar;51(3):881-90 – reference: 20820187 - Prostate Cancer Prostatic Dis. 2010 Dec;13(4):356-61 – reference: 13130303 - Nat Rev Cancer. 2003 Oct;3(10):721-32 – reference: 10677529 - Proc Natl Acad Sci U S A. 2000 Feb 15;97(4):1749-53 – reference: 17485898 - Breast Cancer. 2007;14(2):132-49 – reference: 12527919 - Int J Oncol. 2003 Feb;22(2):237-52 – reference: 20495573 - Nat Rev Cancer. 2010 Jun;10(6):389-402 – reference: 20726036 - J Pathol. 2010 Nov;222(3):310-9 – reference: 19218553 - RNA. 2009 Apr;15(4):716-23 – reference: 18768788 - Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13556-61 – reference: 18268015 - J Biol Chem. 2008 Apr 11;283(15):9674-80 – reference: 20841507 - Blood. 2010 Dec 16;116(25):5660-9 – reference: 19717645 - Blood. 2009 Oct 29;114(18):3872-9 – reference: 11114724 - Oncogene. 2000 Nov 16;19(48):5471-6 – reference: 20940405 - Cancer Res. 2010 Oct 15;70(20):8233-46 – reference: 17110380 - J Biol Chem. 2007 Jan 12;282(2):1479-86 – reference: 18077375 - Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20350-5 – reference: 18977327 - Cancer Cell. 2008 Nov 4;14(5):382-93 – reference: 18367714 - RNA. 2008 May;14(5):872-7 – reference: 15944708 - Nature. 2005 Jun 9;435(7043):834-8 – reference: 1333787 - Br J Cancer. 1992 Dec;66(6):1116-21 – reference: 20498641 - Oncogene. 2010 Jul 22;29(29):4225-36 – reference: 20406806 - J Biol Chem. 2010 Jun 18;285(25):19076-84 – reference: 12586780 - Endocrinology. 2003 Mar;144(3):1032-44 – reference: 20422307 - J Gastrointest Surg. 2010 Jul;14(7):1170-9 – reference: 7491141 - N Engl J Med. 1995 Dec 28;333(26):1757-63 – reference: 11779458 - Cell. 2001 Dec 28;107(7):823-6 – reference: 20689545 - Nat Med. 2010 Aug;16(8):853-4 – reference: 19238171 - Cell Res. 2009 Apr;19(4):439-48 – reference: 20628822 - Ann Surg Oncol. 2011 Jan;18(1):253-60 – reference: 16314309 - Nucleic Acids Res. 2005 Nov 27;33(20):e179 – reference: 11252954 - Nat Rev Mol Cell Biol. 2001 Feb;2(2):127-37 – reference: 16878133 - Nat Genet. 2006 Sep;38(9):1060-5 – reference: 10880430 - EMBO J. 2000 Jul 3;19(13):3159-67 – reference: 2469964 - Nature. 1989 May 4;339(6219):58-61 – reference: 20103628 - Cancer Res. 2010 Feb 1;70(3):1204-14 – reference: 11896390 - Nat Genet. 2002 Apr;30(4):363-4 |
| SSID | ssj0000396248 |
| Score | 2.113492 |
| Snippet | MicroRNAs （miRNAs） play an important role in carcinogenesis in various solid cancers including breast can-cer. Down-regulation of microRNA-148a （miR-148a） has... MicroRNAs (miRNAs) play an important role in carcinogenesis in various solid cancers including breast cancer. Down-regulation of microRNA-148a ( miR-148a) has... MicroRNAs (miRNAs) play an important role in carcinogenesis in various solid cancers including breast cancer. Down-regulation of microRNA-148a (miR-148a) has... MicroRNAs (miRNAs) play an important role in carcinogenesis in various solid cancers including breast cancer. Down-regulation of microRNA - 148a ( miR - 148a )... |
| SourceID | pubmedcentral proquest pubmed crossref elsevier chongqing |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 170 |
| SubjectTerms | angiogenesis breast cancer ERBB3 MCF7细胞 microRNA microRNA-148a MIR miRNA Research Paper 乳腺癌细胞 生物学作用 白血病病毒 肿瘤血管生成 |
| SummonAdditionalLinks | – databaseName: Elsevier SD Freedom Collection dbid: .~1 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnR3LbtQw0Kp6QL1UFPpICyhIHODg7jqxY-dIq1YV0nIoVOrN8nPXEsoWdnvgwrczkxdsK1SJq-Ox7JnJPOx5EPKOYbKii4EyV5eU26mg1gdBQ6iq2jngsbZbw-xzdXXDP92K2y1yPuTCYFhlL_s7md5K635k0mNzcpfS5AvGzyvkT4ZvSwUmmnMukctPf7HxnmVa1lXRNtHC-RQB_iTydIu0g-8Z-9CuQwWWWVgsm_l3UB7_UlePzdGHUZV_qanL52S3ty_zj90R9shWaF6QZ7P-Bf0lYbN0TcE5MXlqFsmm9So3zTwt5yjz0iq3P_MuOBx2lV9cn52V--Tm8uLr-RXt2yZQB-7BmoIBJg2IjRitNLXw9dR4I3yMPjLHrK1tAUaSgzPHIiplghS-lLIMJnLpmCkPyHazbMIRyWujXIxc8Gg8aLtCVbJwYEIxzz03TmXkeMSUvuvKY2jweTlSJiN8QJ12fcFx7HvxTY-RZYh9jdgHR0S32NciI6cj2LDkEwBqoIveYB0NWuEp0LcDHTX8VvhWYpqwvF9pOCwvFbYvzchhR9dxNwXaaJWqMiI3KD5OwJLdm1-atGhLd5fgv4EFdfz_Wz4hO921NsZcviLb6x_34TXYRWv7pmX837z8AsM priority: 102 providerName: Elsevier |
| Title | MiR-148a inhibits angiogenesis by targeting ERBB3 |
| URI | http://lib.cqvip.com/qk/85389A/201103/38347483.html https://dx.doi.org/10.1016/S1674-8301(11)60022-5 https://www.ncbi.nlm.nih.gov/pubmed/23554686 https://www.proquest.com/docview/1324388575 https://pubmed.ncbi.nlm.nih.gov/PMC3597061 |
| Volume | 25 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1La9wwEB6SFEovJX07aYMLPbQHLZElWfIhhKYkhML2ELqQm9Bz1xC8TXYDzaW_vSO_2rQp6dkeWZoZab6x5gHwjqZkRRcDoa5ihNt9QawPgoRQlpVzqGNtt4bpl_J0xj-fi_MNGAoq9Axc3enapX5Ss6uLyffLm0Pc8Adjtm-KpCcKVfU9pR_KNkBdbMIDNE4y7dVpj_jbw5lVZdH21BqJfuX13D1SqrqwWDbzS7Ql_7Jef6PTP4Msf7NaJ9vwuIeb-cdOP57ARmiewsNpf6H-DOi0PiPoq5i8bha1rder3DTzejlPR2C9yu1N3sWK46zy47OjI_YcZifHXz-dkr6LAnHoLawJ4jFp8BSJ0UpTCV_tG2-Ej9FH6qi1lS0QMzlccyyiUiZI4ZmULJjIpaOGvYCtZtmEV5BXRrkYueDReDR-hSpl4RBRUc89N05lsDNySn_rqmVodIG55IplwAfWadfXH09tMC70GGiWuK8T99Ev0S33tchgMpINQ95DoAa56B5FdOhAo87cR_p2kKPGXZauTkwTltcrjYvlTKVuphm87OQ6zqZIkK1UZQbylsTHF1IF79tPmnrRVvJm6M4hoNr5j-_uwqPud3aKtXwNW-ur6_AG8dDa7sHm5Afda_X8Jx-6ANw |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LbxQxDLZKkYBLxZspr0HiAId0NzPJPI60arVAt4fSSr1FmTx2I6HZtrs99NLfXntesCBUiWtmHCV2Yn9OHBvgI6fHisY7xk2ZMlGNJausk8y5LCuNwTXWVGuYHmWTU_HtTJ5twF7_FobCKjvd3-r0Rlt3LaOOm6PzEEY_KH6-oPXJ6W4pkffgvsDtS7tz54YPBy3jtMySpooWETCi-PWSp-2lafzE-eemIyYpz8J8Uc8u0Hr8y179jUf_DKv8zU4dPIatDmDGX9o5PIENVz-FB9PuCv0Z8Gk4Zuid6DjU81CF1TLW9SwsZqT0wjKuruM2OhxHFe8f7-6mz-H0YP9kb8K6ugnMoH-wYojAco16w_sq16W05VhbLa331nPDq6qsEkRJBufsE18U2uXSpnmeOu1FbrhOX8BmvajdK4hLXRjvhRReWzR3SZHliUEMxa2wQpsigu2BU-q8zY-h0OkVJJoIRM86ZbqM41T44qcaQsuI-4q4j56IarivZAQ7A1nf5R0ERS8XtbZ2FJqFu0g_9HJUuK_oskTXbnG1VDhZkRZUvzSCl61ch9EkBNKyIosgX5P48APl7F7_Uod5k7s7RQcOIdT2_w_5PTycnEwP1eHXo--v4VF7xk0BmG9gc3V55d4iSFpV75pNcAu4fwXe |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=MiR-148a+inhibits+angiogenesis+by+targeting+ERBB3&rft.jtitle=Journal+of+biomedical+research&rft.au=Yu%2C+Jing&rft.au=Li%2C+Qi&rft.au=Xu%2C+Qing&rft.au=Liu%2C+Lingzhi&rft.date=2011-05-01&rft.issn=1674-8301&rft.volume=25&rft.issue=3&rft.spage=170&rft_id=info:doi/10.1016%2FS1674-8301%2811%2960022-5&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_s | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fimage.cqvip.com%2Fvip1000%2Fqk%2F85389A%2F85389A.jpg |